多黏菌素B与黏菌素肾毒性比较:集成学习与倾向性评分匹配证据
该回顾性研究纳入258例肾功能正常至中度受损患者(黏菌素132例,多黏菌素B 126例),采用机器学习预测急性肾损伤(AKI)风险并用倾向性评分匹配比较肾毒性。结果显示黏菌素组肾毒性(KDIGO AKI≥II期)显著高于多黏菌素B组,匹配后黏菌素偏好使用与肾毒性风险显著相关(OR 3.42)。
要点
- 黏菌素肾毒性(KDIGO AKI≥II期)发生率显著高于多黏菌素B。
- 匹配队列中黏菌素偏好使用与肾毒性风险显著相关(OR 3.42)。
- AKI后30天内仅41%病例实现完全肾功能恢复。
核心结论
- 黏菌素肾毒性显著高于多黏菌素B。
- 基线肾功能与AKI风险关系复杂,中度肾损害患者无论选用何种多黏菌素均需密切监测。
研究设计与样本
- 回顾性分析258例肾功能正常至中度受损患者,其中黏菌素132例、多黏菌素B 126例。
- 采用机器学习算法预测AKI风险,并用倾向性评分匹配评估黏菌素偏好于多黏菌素B的风险。
主要发现
- 未匹配队列中黏菌素组肾毒性(KDIGO AKI≥II期)发生率为31%,多黏菌素B组为19%(P=0.04)。
- 匹配队列中黏菌素组肾毒性发生率为34.4%,多黏菌素B组为14.1%(P=0.01)。
- 机器学习识别出的主要预测因素包括较低基线eGFR、较高尿酸、低白蛋白血症、较高年龄、合并肾毒性药物、体重、血管升压药使用及多黏菌素类型。
- 黏菌素偏好于多黏菌素B在未匹配队列中肾毒性风险OR为2.08(95%CI 1.14-3.79),匹配队列中OR为3.42(95%CI 1.38-8.5)。
- AKI病例中30天内完全肾功能恢复者仅占41%。
临床怎么用
- 临床选用多黏菌素时,应优先评估肾毒性风险,黏菌素肾毒性风险高于多黏菌素B。
- 对中度肾功能损害患者,无论选用黏菌素或多黏菌素B,均需密切监测肾功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polymyxins are last-resort antibiotics for multidrug-resistant Gram-negative infections, but their nephrotoxicity limits clinical use. OBJECTIVES: To compare the nephrotoxicity of colistin versus polymyxin B and identify risk factors for acute kidney injury (AKI). METHODS: We retrospectively analysed 258 patients (132 colistin, 126 polymyxin B) with normal to moderately impaired renal function. Machine learning (ML) algorithms predicted AKI risk, and propensity score matching was used to evaluate the risk of colistin preference over polymyxin B. RESULTS: Colistin nephrotoxicity (defined as at least stage II KDIGO AKI) was significantly more frequent with colistin than polymyxin B in both unmatched (for colistin 31% versus for polymyxin B 19%, P = 0.04) and matched cohorts (34.4% for colistin versus 14.1% for polymyxin B, P = 0.01). ML identified lower baseline eGFR, higher uric acid, hypalbuminaemia, higher age, concomitant nephrotoxic drug use, weight, vasopressor use and polymyxin type as top predictors. Colistin preference over polymyxin B resulted in significant nephrotoxicity risk in both unmatched (OR: 2.08, 95% CI [1.14-3.79]) and matched cohorts (OR: 3.42, 95% CI [1.38-8.5]). Complete renal recovery occurred in only 41% of AKI cases within 30 days. CONCLUSIONS: Colistin demonstrates significantly higher nephrotoxicity than polymyxin B. The complex relationship between baseline renal function and AKI risk suggests careful monitoring for patients with moderate renal impairment, regardless of polymyxin choice.
引用
- Özdede M, Balli Turhan FN, Geridönmez Ö, et al. Comparative nephrotoxicity of polymyxin B versus colistin: evidence from ensemble learning and propensity score matching. J Antimicrob Chemother. 2026. PMID: 42115839. doi:10.1093/jac/dkag044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。